Pharming Group N.V. has reached an agreement with the Spanish Ministry of Health to grant reimbursement for Ruconest (conestat alfa) in Spain. Ruconest is the first and only plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy approved for the treatment of acute HAE attacks in adults and children aged 2 years and over.
Clinical trial evidence has demonstrated that rhC1INH is efficacious and well-tolerated, and these results have been further confirmed in real-world observational studies.
Mrs Sarah Smith, President of the Spanish HAE Patient Association (AEDAF), says: “We welcome the approval of new treatments which might help alleviate the suffering of patients with HAE.” And Sijmen de Vries, CEO of Pharming, comments: “We are delighted with this positive reimbursement decision by the Spanish Ministry of Health, as it means patients in Spain in need of new treatment options for HAE will now be able to access Ruconest. We look forward to working with the Spanish healthcare community to ensure a rapid rollout of the product.”